Glioblastoma (combination with active agents / newly diagnosed or recurrent) | XPORT-GBM-029
Indication: GBM
Title: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Drug: selinexor
Please visit clinicaltrials.gov for more information about this study.
Phase 1 | Phase 2 | Phase 3 | Commercial |
---|---|---|---|
Phase 1 | Phase 2 | Phase 3 | Commercial |